How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
28
IGC Quote, Financials, Valuation and Earnings
Last price:
$0.27
Seasonality move
:
3.53%
Day range:
$0.27 - $0.28
52-week range:
$0.25 - $0.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.26x
P/B ratio:
3.10x
Volume:
354.5K
Avg. volume:
674.5K
1-year change:
-16.74%
Market cap:
$25.1M
Revenue:
$1.3M
EPS (TTM):
-$0.08
Analysts' Opinion
-
Consensus RatingIGC Pharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.88, IGC Pharma, Inc. has an estimated upside of 1335.19% from its current price of $0.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.27.
Fair Value
-
According to the consensus of 2 analysts, IGC Pharma, Inc. has 1335.19% upside to fair value with a price target of $3.88 per share.
IGC vs. S&P 500
-
Over the past 5 trading days, IGC Pharma, Inc. has underperformed the S&P 500 by -7.53% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IGC Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IGC Pharma, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter IGC Pharma, Inc. reported revenues of $191K.
Earnings Growth
-
IGC Pharma, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter IGC Pharma, Inc. reported earnings per share of -$0.02.
Enterprise value:
24.1M
EV / Invested capital:
--
Price / LTM sales:
20.26x
EV / EBIT:
--
EV / Revenue:
21.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2K
Return On Assets:
-70.25%
Net Income Margin (TTM):
-582.82%
Return On Equity:
-94.42%
Return On Invested Capital:
-91.27%
Operating Margin:
-1517.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3M | $1.2M | $1.1M | $412K | $191K | |
| Gross Profit | $25K | $92K | $2K | $53K | -$6K | |
| Operating Income | -$10.9M | -$9.3M | -$8.1M | -$1.8M | -$2.9M | |
| EBITDA | -$10.3M | -$8.7M | -$7.5M | -$1.6M | -$2.8M | |
| Diluted EPS | -$0.20 | -$0.19 | -$0.08 | -$0.02 | -$0.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.7M | $11.2M | $6.1M | $4.3M | $2M | |
| Total Assets | $33.8M | $22M | $16.5M | $10.4M | $9.7M | |
| Current Liabilities | $2M | $1.4M | $2.1M | $2.8M | $1.5M | |
| Total Liabilities | $2.6M | $1.8M | $2.4M | $3M | $1.7M | |
| Total Equity | $31.3M | $20.1M | $14.1M | $7.4M | $8.1M | |
| Total Debt | $550K | $417K | $285K | $170K | $137K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.3M | -$4.9M | -$5.5M | -$996K | -$2.1M | |
| Cash From Investing | -$192K | -$580K | -$40K | -$65K | -$374K | |
| Cash From Financing | $2.9M | $4M | $5.1M | $794K | $3.1M | |
| Free Cash Flow | -$6.9M | -$5.5M | -$6.3M | -$1.1M | -$2.4M | |
IGC
Sector
Market Cap
$25.1M
$24.3M
Price % of 52-Week High
54.16%
50%
Dividend Yield
0%
0%
Shareholder Yield
-13.24%
-1.67%
1-Year Price Total Return
-16.74%
-21.43%
Beta (5-Year)
0.322
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.29
200-day SMA
Sell
Level
$0.34
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.29
Relative Strength Index (RSI14)
Sell
Level
35.92
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-93.6768
50-day SMA
Sell
Level
$0.30
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.1798)
Sell
CA Score
(Annual)
Level (-2.947)
Buy
Beneish M-Score
(Annual)
Level (-2.6019)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.3573)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Stock Forecast FAQ
In the current month, IGC has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IGC average analyst price target in the past 3 months is $3.88.
-
Where Will IGC Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that IGC Pharma, Inc. share price will rise to $3.88 per share over the next 12 months.
-
What Do Analysts Say About IGC Pharma, Inc.?
Analysts are divided on their view about IGC Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IGC Pharma, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is IGC Pharma, Inc.'s Price Target?
The price target for IGC Pharma, Inc. over the next 1-year time period is forecast to be $3.88 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IGC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IGC Pharma, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IGC?
You can purchase shares of IGC Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IGC Pharma, Inc. shares.
-
What Is The IGC Pharma, Inc. Share Price Today?
IGC Pharma, Inc. was last trading at $0.27 per share. This represents the most recent stock quote for IGC Pharma, Inc.. Yesterday, IGC Pharma, Inc. closed at $0.27 per share.
-
How To Buy IGC Pharma, Inc. Stock Online?
In order to purchase IGC Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IGC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IGC
Sector
P/E ratio
--
23.33x
PEG ratio
--
-0.01x
P/B ratio
3.10x
1.78x
Price / LTM sales
20.26x
1.53x
Growth Metrics
IGC
Sector
Revenue growth
-53.64%
4%
Earnings growth
11.06%
11.06%
Revenue (5-year growth)
-20.77%
6.22%
Earnings forecast
-$0.02
-$0.19
Profitability
IGC
Sector
Profitability FY 2024
$52K
$3M
Return on invested capital
-91.27%
-33.25%
Return on assets
-70.25%
-29.67%
Return on equity
-94.42%
-38.89%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Jan
31
Estimated Next Earnings Date
May
2
Balance Sheet
IGC
Sector
Total cash
$1.1M
$25M
Short term investments
--
$24.9M
Total assets
$8.7M
$72.5M
Long term debt
$137K
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
